Product Overview
Mechanism Of Action
Efficacy and Dosing
Safety and Tolerability
Guidelines Support
Case Studies
PI
Safety
med_info
Contact Information
Contact A Representative

Medical Information CONTACT

Health care professionals and patients may request specific medical information about Cardene from the Medical Information department by contacting:

Phone number: (877) 207-5802
Email: medinfo@ekrtx.com

Mailing Address:
EKR Therapeutics, Inc.
1545 US Highway 206, 3rd Floor
Bedminster, NJ 07921

Additionally, a completed Medical Information Request Form can be faxed to:
(877) 395-2958

Medical Information Request Form

To view PDF documents, you must have the Adobe® Acrobat® Reader® installed on your computer.

Click here to view our Privacy Policy.

 

Important Safety Information
Close monitoring of the blood pressure is required during therapy. CARDENE I.V. is contraindicated in patients with known hypersensitivity to the drug and in patients with advanced aortic stenosis. Reduction of diastolic pressure and reduced afterload may worsen rather than improve myocardial oxygen balance. Caution is advised when administering CARDENE I.V. to patients with impaired renal or hepatic function, in combination with a beta-blocker in patients with congestive heart failure, or portal hypertension. Observe caution in patients with significant left ventricular dysfunction due to possible negative inotropic effect. CARDENE I.V. gives no protection against the dangers of abrupt beta-blocker withdrawal; beta-blocker dosage should be gradually reduced. Levels of cyclosporine should be closely monitored during therapy. The most common side effects of CARDENE I.V. are headache (14.6%), hypotension (5.6%), nausea/vomiting (4.9%), and tachycardia (3.5%). Less frequent adverse effects, in each case occurring at 1.4%, include ECG abnormalities, postural hypotension, ventricular extrasystoles, injection-site reaction, dizziness, sweating and polyuria.

Please see full prescribing information.
     

 

© EKR Therapeutics, Inc. All rights reserved. July 2008.